Items where authors include "Jackson, G"

Export as [feed] Atom [feed] RSS
Number of items: 28.

Article

Shahin, M, Pawlyn, C, Weinhold, N et al. (14 more authors) (2022) The Impact of Autologous Stem Cell Transplantation on the Genetics of High-Risk Relapsed Multiple Myeloma. Blood, 140 (Supplement 1). pp. 4232-4233. ISSN 0006-4971

Royle, K-L orcid.org/0000-0003-0225-1199, Coulson, AB, Ramasamy, K et al. (26 more authors) (2022) Risk and response adapted therapy following autologous stem cell transplant in patients with newly diagnosed multiple myeloma (RADAR (UK-MRA Myeloma XV Trial): study protocol for a phase II/III randomised controlled trial. BMJ Open, 12 (11). e063037. ISSN 2044-6055

D'Agostino, M, Cairns, DA orcid.org/0000-0002-2338-0179, Lahuerta, JJ et al. (28 more authors) (2022) Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project. Journal of Clinical Oncology, 40 (29). pp. 3406-3420. ISSN 0732-183X

Coulson, AB, Royle, K-L orcid.org/0000-0003-0225-1199, Pawlyn, C et al. (22 more authors) (2022) Frailty-adjusted therapy in Transplant Non-Eligible patients with newly diagnosed Multiple Myeloma (FiTNEss (UK-MRA Myeloma XIV Trial)): a study protocol for a randomised phase III trial. BMJ Open, 12 (6). e056147. ISSN 2044-6055

Pawlyn, C, Cairns, D orcid.org/0000-0002-2338-0179, Menzies, T orcid.org/0000-0003-3896-7228 et al. (11 more authors) (2022) Autologous stem cell transplantation is safe and effective for fit older myeloma patients: exploratory results from the Myeloma XI trial. Haematologica, 107 (1). pp. 231-242. ISSN 0390-6078

Giles, HV, Cook, MA, Drayson, MT et al. (12 more authors) (2021) Redefining Non-measurable Multiple Myeloma Using Mass Spectrometry. Blood. ISSN 0006-4971

Ludwig, H, Sonneveld, P, Facon, T et al. (33 more authors) (2021) COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network. The Lancet Haematology, 8 (12). e934-e946. ISSN 2352-3026

Bird, S, Cairns, D orcid.org/0000-0002-2338-0179, Menzies, T orcid.org/0000-0003-3896-7228 et al. (12 more authors) (2021) Sex Differences in Multiple Myeloma Biology but not Clinical Outcomes: Results from 3894 Patients in the Myeloma XI Trial. Clinical Lymphoma Myeloma and Leukemia, 21 (10). pp. 667-675. ISSN 2152-2650

Croft, J, Ellis, S, Sherborne, AL et al. (19 more authors) (2021) Copy number evolution and its relationship with patient outcome—an analysis of 178 matched presentation-relapse tumor pairs from the Myeloma XI trial. Leukemia, 35 (7). pp. 2043-2053. ISSN 0887-6924

Weinhold, N, Salwender, HJ, Cairns, DA orcid.org/0000-0002-2338-0179 et al. (15 more authors) (2021) Chromosome 1q21 abnormalities refine outcome prediction in patients with multiple myeloma – a meta-analysis of 2,596 trial patients. Haematologica. ISSN 0390-6078

Bygrave, C, Pawlyn, C, Davies, F et al. (11 more authors) (2021) Early relapse after high‐dose melphalan autologous stem cell transplant predicts inferior survival and is associated with high disease burden and genetically high‐risk disease in multiple myeloma. British Journal of Haematology, 193 (3). pp. 551-555. ISSN 0007-1048

Rana, R, Cockwell, P, Drayson, M et al. (8 more authors) (2020) Renal outcome in patients with newly diagnosed multiple myeloma: results from the UK NCRI Myeloma XI trial. Blood Advances, 4 (22). pp. 5836-5845. ISSN 2473-9529

Shah, V, Sherborne, AL, Johnson, DC et al. (16 more authors) (2020) Predicting ultrahigh risk multiple myeloma by molecular profiling: an analysis of newly diagnosed transplant eligible myeloma XI trial patients. Leukemia, 34. pp. 3091-3096. ISSN 0887-6924

Hoang, PH, Cornish, AJ, Sherborne, AL et al. (8 more authors) (2020) An enhanced genetic model of relapsed IGH-translocated multiple myeloma evolutionary dynamics. Blood Cancer Journal, 10 (10). 101. ISSN 2044-5385

Bradbury, CA, Craig, Z orcid.org/0000-0001-9930-6648, Cook, G orcid.org/0000-0003-0223-3652 et al. (14 more authors) (2020) Thrombosis in Patients with Myeloma Treated in the Myeloma IX and Myeloma XI Phase III Randomized Controlled Trials. Blood. ISSN 0006-4971

Pawlyn, C, Cairns, D orcid.org/0000-0002-2338-0179, Kaiser, M et al. (11 more authors) (2020) The relative importance of factors predicting outcome for myeloma patients at different ages: results from 3894 patients in the Myeloma XI trial. Leukemia, 34 (2). pp. 604-612. ISSN 0887-6924

Shah, V, Johnson, DC, Sherborne, AL et al. (19 more authors) (2018) Subclonal TP53 copy number is associated with prognosis in multiple myeloma. Blood, 132 (23). pp. 2465-2469. ISSN 0006-4971

Gay, F, Jackson, G, Rosiñol, L et al. (28 more authors) (2018) Maintenance Treatment and Survival in Patients With Myeloma: A Systematic Review and Network Meta-analysis. JAMA Oncology, 4 (10). pp. 1389-1397. ISSN 2374-2437

Heaney, JLJ, Campbell, JP, Iqbal, G et al. (11 more authors) (2018) Characterisation of immunoparesis in newly diagnosed myeloma and its impact on progression-free and overall survival in both old and recent myeloma trials. Leukemia, 32 (8). pp. 1727-1738. ISSN 0887-6924

Ludwig, H, Delforge, M, Facon, T et al. (29 more authors) (2018) Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network. Leukemia, 32 (7). pp. 1542-1560. ISSN 0887-6924

Johnson, DC, Lenive, O, Mitchell, J et al. (14 more authors) (2017) Neutral tumor evolution in myeloma is associated with poor prognosis. Blood, 130 (14). pp. 1639-1643. ISSN 0006-4971

Sabir, SR orcid.org/0000-0003-0611-6226, Yeoh, S, Jackson, G et al. (1 more author) (2017) EML4-ALK variants: biological and molecular properties, and the implications for patients. Cancers, 9 (9). 118. ISSN 2072-6694

Heaney, JLJ, Campbell, JP, Griffin, AE et al. (8 more authors) (2017) Diagnosis and monitoring for light chain only and oligosecretory myeloma using serum free light chain tests. British Journal of Haematology, 178 (2). pp. 220-230. ISSN 0007-1048

Conference or Workshop Item

Cook, G, Pawlyn, C, Royle, K-L et al. (20 more authors) (2021) Fitness, a UK Myeloma Research Alliance (UK-MRA) Frailty-Adjusted Therapy Study, Supports the Feasibility of Recruiting Frail Newly Diagnosed Myeloma Patients to Large Clinical Trials. In: 63rd American Society of Hematology Annual Meeting, 11-14 Dec 2021, Atlanta, Georgia, USA.

Proceedings Paper

Yong, K, Royle, K-L orcid.org/0000-0003-0225-1199, Ramasamy, K et al. (23 more authors) (2022) Risk-Adapted Therapy Directed According to Response (RADAR, UK-MRA Myeloma XV) - Comparing MRD-Guided Treatment Escalation and De-Escalation Strategies in Patients with Newly Diagnosed Myeloma Suitable for Stem Cell Transplantation. In: Blood. 64th ASH Annual Meeting, 10-13 Dec 2022, New Orleans, Louisiana. American Society of Hematology , pp. 1844-1846.

Bygrave, CA, Pawlyn, C, Davies, FE et al. (19 more authors) (2018) Progression Free Survival below 12 Months Following Stem Cell Transplant Is a Hallmark of High-Risk Myeloma Which Is Associated with Inferior Overall Survival — Data from the Ukmrc Myeloma XI Trial. In: Blood. ASH 2018 – 60th American Society of Hematology Annual Meeting and Exposition, 01-04 Dec 2018, San Diego, CA. American Society of Hematology .

Sherborne, AL, Shah, V, Ellis, S et al. (15 more authors) (2017) Improving Outcomes for Patients with High-Risk Myeloma Via Prospective Trial Evidence: The Myeloma UK Nine Optimum Trial. In: Blood. 59th ASH Annual Meeting and Exposition, 09-12 Dec 2017, Atlanta, GA, USA. American Society of Hematology , p. 1767.

Walker, BA, Wardell, CP, Murison, A et al. (18 more authors) (2014) Apobec Family Mutational Signatures Are Associated with Poor Prognosis Translocations in Multiple Myeloma. In: BLOOD. 56th ASH Annual Meeting 2014, 06-09 Dec 2014, San Francisco, California, USA. American Society of Hematology .

This list was generated on Sat Mar 23 23:22:57 2024 GMT.